BSE Live
Sep 08, 12:55Prev. Close
934.05
Open Price
934.05
Bid Price (Qty.)
944.35 (37)
Offer Price (Qty.)
945.40 (75)
NSE Live
Sep 08, 12:55Prev. Close
933.45
Open Price
935.00
Bid Price (Qty.)
944.80 (56)
Offer Price (Qty.)
945.00 (10)
Profit & Loss account of Tata Chemicals (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
INCOME | ||||||
Revenue From Operations [Gross] | 4,415.00 | 4,360.00 | 4,915.00 | 3,707.47 | 2,984.26 | |
Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Revenue From Operations [Net] | 4,415.00 | 4,360.00 | 4,915.00 | 3,707.47 | 2,984.26 | |
Total Operating Revenues | 4,441.00 | 4,384.00 | 4,930.00 | 3,720.93 | 2,998.88 | |
Other Income | 319.00 | 383.00 | 301.00 | 277.93 | 219.15 | |
Total Revenue | 4,760.00 | 4,767.00 | 5,231.00 | 3,998.86 | 3,218.03 | |
EXPENSES | ||||||
Cost Of Materials Consumed | 1,141.00 | 1,003.00 | 1,138.00 | 814.14 | 600.33 | |
Purchase Of Stock-In Trade | 46.00 | 86.00 | 130.00 | 160.35 | 152.56 | |
Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Changes In Inventories Of FG,WIP And Stock-In Trade | -8.00 | 24.00 | -107.00 | -42.95 | 11.59 | |
Employee Benefit Expenses | 293.00 | 299.00 | 274.00 | 248.46 | 250.42 | |
Finance Costs | 144.00 | 49.00 | 26.00 | 19.28 | 18.74 | |
Depreciation And Amortisation Expenses | 369.00 | 295.00 | 245.00 | 222.41 | 197.32 | |
Other Expenses | 2,151.00 | 2,097.00 | 2,260.00 | 1,589.56 | 1,373.10 | |
Total Expenses | 4,136.00 | 3,853.00 | 3,966.00 | 3,011.25 | 2,604.06 | |
Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 624.00 | 914.00 | 1,265.00 | 987.61 | 613.97 | |
Exceptional Items | 0.00 | 102.00 | 0.00 | 0.00 | 0.00 | |
Profit/Loss Before Tax | 624.00 | 1,016.00 | 1,265.00 | 987.61 | 613.97 | |
Tax Expenses-Continued Operations | ||||||
Current Tax | 41.00 | 64.00 | 239.00 | 204.01 | 134.49 | |
Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Deferred Tax | 59.00 | 56.00 | -1.00 | -2.90 | 0.37 | |
Tax For Earlier Years | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Total Tax Expenses | 100.00 | 120.00 | 238.00 | 201.11 | 134.86 | |
Profit/Loss After Tax And Before ExtraOrdinary Items | 524.00 | 896.00 | 1,027.00 | 786.50 | 479.11 | |
Profit/Loss From Continuing Operations | 571.00 | 896.00 | 1,027.00 | 786.50 | 479.11 | |
Profit/Loss For The Period | 557.00 | 896.00 | 1,027.00 | 801.56 | 479.11 | |
OTHER ADDITIONAL INFORMATION | ||||||
EARNINGS PER SHARE | ||||||
Basic EPS (Rs.) | 21.87 | 35.17 | 40.31 | 31.46 | 18.81 | |
Diluted EPS (Rs.) | 21.87 | 35.17 | 40.31 | 31.46 | 18.81 | |
VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
Imported Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Indigenous Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
STORES, SPARES AND LOOSE TOOLS | ||||||
Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
Equity Share Dividend | 382.00 | 446.00 | 318.00 | 254.76 | 280.23 | |
Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Equity Dividend Rate (%) | 110.00 | 150.00 | 175.00 | 125.00 | 100.00 |
30.07.2025
29.07.2025
Tata Chemicals Consolidated June 2025 Net Sales at Rs 3,719.00 crore, down 1.85% Y-o-Y
28.07.2025
Tata Chemicals Standalone June 2025 Net Sales at Rs 1,169.00 crore, up 11.65% Y-o-Y
28.07.2025
14.04.2022
Tata Chemical Q4 PAT seen up 2,546.1% YoY to Rs. 311.4 cr: ICICI Direct
17.01.2022
Tata Chemical Q3 PAT seen up 64.3% YoY to Rs. 264.3 cr: ICICI Direct
19.10.2021
Tata Chemicals Q2 PAT seen up 336.8% YoY to Rs 307.8 cr: ICICI Direct
13.07.2021
Tata Chemical Q1 PAT seen up 911.3% YoY to Rs. 134.3 cr: ICICI Direct
07.05.2019
Q4 earnings shows Tata Chemicals is on the mend, but Europe sours
06.05.2019
Why this Indian MNC beverage company is looking attractive at current levels?
06.02.2019
Tata Chemicals Q3 review: Soft quarter, one-offs weigh on profits
06.11.2018
Tata Chemicals: Weak Q2; capital infusion in high margin business could trigger a re-rating
15.03.2018
24.04.2017
24.04.2017
20.04.2017